SGLT2抑制剂与GLP-1受体激动剂降低2型糖尿病患者肺炎和严重脓毒症风险的真实世界队列分析
基于TriNetX全球电子病历的回顾性队列研究,采用活性对照新使用者设计,倾向性评分1:1匹配后随访12个月。与DPP-4抑制剂相比,SGLT2抑制剂与肺炎(HR 0.75)和严重脓毒症(HR 0.75)风险降低相关;GLP-1受体激动剂同样与肺炎(HR 0.60)和严重脓毒症(HR 0.61)风险降低相关。
要点
- 与DPP-4i相比,SGLT2i与肺炎和严重脓毒症风险降低相关(HR均为0.75)。
- 与DPP-4i相比,GLP-1 RA与肺炎(HR 0.60)和严重脓毒症(HR 0.61)风险降低相关。
- 结果来自真实世界队列,尚需随机对照试验验证。
核心结论
- 在2型糖尿病患者中,SGLT2抑制剂和GLP-1受体激动剂与肺炎及严重脓毒症发生风险降低相关。
研究设计与样本
- 回顾性队列研究,使用TriNetX全球联邦数据库的匿名电子病历。
- 采用活性对照新使用者设计,进行两项意向性治疗分析,每项含两个成人2型糖尿病队列。
- 第一项分析比较SGLT2i与DPP-4i,第二项比较GLP-1 RA与DPP-4i,均经倾向性评分1:1匹配,随访12个月。
- 次要分析比较SGLT2i和GLP-1 RA与其他降糖治疗。
主要发现
- SGLT2i vs DPP-4i匹配后纳入352 687例,SGLT2i与肺炎风险降低相关(HR 0.75,95%CI 0.73–0.78),与严重脓毒症风险降低相关(HR 0.75,95%CI 0.73–0.77)。
- GLP-1 RA vs DPP-4i匹配后纳入331 863例,GLP-1 RA与肺炎风险降低相关(HR 0.60,95%CI 0.58–0.62),与严重脓毒症风险降低相关(HR 0.61,95%CI 0.59–0.63)。
临床怎么用
- 对2型糖尿病患者选择降糖方案时,SGLT2i或GLP-1 RA可能与肺炎和严重脓毒症风险降低相关,可结合心肾获益综合考量。
局限性
- 为回顾性真实世界队列研究,存在残余混杂可能,结论需随机对照试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are treatments for type 2 diabetes (T2D). Beyond glucose-lowering and cardiorenal protection, these drugs may protect against pneumonia and sepsis. AIMS: This study assesses the impact of SGLT2i and GLP-1 RAs on the risk of incident pneumonia and severe sepsis. METHODS: A retrospective cohort study was conducted using anonymised electronic medical records from TriNetX, a global federated database. Two intention-to-treat analyses were performed, each with two cohorts of adult T2D patients. The first analysis compared individuals prescribed SGLT2i, and the second individuals prescribed GLP-1 RAs, with those prescribed dipeptidyl peptidase-4 inhibitors (DPP-4i). An active comparator new user design was used, with outcomes defined as time-to-incident pneumonia and severe sepsis. Propensity score matching (1:1) was applied to control for potential confounders, and patients were followed for 12 months. Secondary analyses compared SGLT2i and GLP-1 RAs against other glucose-lowering therapies. RESULTS: After propensity score matching, 352 687 patients were included in the SGLT2i versus DPP-4i comparison. SGLT2i treatment was associated with a risk reduction in incident pneumonia (HR 0.75 (95% CI 0.73, 0.78)) and severe sepsis (0.75 (0.73, 0.77)). In the GLP-1 RA versus DPP-4i comparison, 331 863 patients were included. GLP-1 RA treatment was associated with a risk reduction in incident pneumonia (0.60 (0.58, 0.62)) and severe sepsis (0.61 (0.59, 0.63)). CONCLUSION: SGLT2i and GLP-1 RAs are associated with a reduced risk of incident pneumonia and severe sepsis in patients with T2D. Further research and focused randomised controlled trials are warranted to explore the broader clinical implications of these treatments.
引用
- Henney AE, Riley DR, Hydes TJ, et al. Comparative estimate of glucose-lowering therapies on risk of incident pneumonia and severe sepsis: an analysis of real-world cohort data. Thorax. 2024. PMID: 39645259. doi:10.1136/thorax-2024-221906
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。